keyword
MENU ▼
Read by QxMD icon Read
search

Lung cancer, NSCLC, SCLC

keyword
https://www.readbyqxmd.com/read/28521472/cd117-expression-is-a-predictive-marker-for-poor-prognosis-in-patients-with-non-small-cell-lung-cancer
#1
Tomohiko Sakabe, Junya Azumi, Tomohiro Haruki, Yoshihisa Umekita, Hiroshige Nakamura, Goshi Shiota
Non-small cell lung cancer (NSCLC) accounts for >85% of incidences of lung cancer, for which the predicted 5-year survival rates are low and recurrence rates remain high. Although it has been reported that the patients with SCLC cells that possess the cluster of differentiation (CD) 117 marker exhibited poor prognosis and poor response to chemotherapy, no studies concerning the association of CD117 expression with prognosis of the patients with NSCLC have been reported. An in vitro study reportedly revealed that CD117-positive cell populations in NSCLC cell lines exhibited cancer stem cell (CSC) phenotypes including self-renewal and chemoresistance...
May 2017: Oncology Letters
https://www.readbyqxmd.com/read/28502129/diagnostic-role-of-rassf1a-and-p16ink4a-promoter-gene-hypermethylation-in-serum-dna-of-lung-cancer-patients-clinicopathological-significance
#2
Wafaa T El-Sherif, Sohair K Sayed, Sherif H Galal, Hoda A Makhlouf, Alaa T Hassan, Hosam A Yousef
The most common inactivation mechanism of tumor suppressor genes, RASSF1A and p16INK4a, in lung cancer is hypermethylation. We detected the methylation status of RASSF1A and p16INK4a in serum of lung cancer patients using methylation-specific PCR and analyzed their clinicopathological significance. Each of RASSF1A and p16INK4a hypermethylation was detected in 31.1% cancer patients but not in benign lung lesion patients. Hypermethylation was preferentially observed in small cell lung cancer (SCLC) for RASSF1A (50%), but not for p16INK4a...
June 2016: Egyptian Journal of Immunology
https://www.readbyqxmd.com/read/28482670/immune-checkpoint-inhibitors-in-lung-cancer-current-status-and-future-directions
#3
Yun Fan, Weimin Mao
Recently, the immune checkpoint inhibitors that target programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) have made a breakthrough in treating advanced non-small cell lung cancer (NSCLC) with the efficacy of approximately 20%; among which, nivolumab has acquired treatment indications in lung squamous cell carcinoma. The inhibitors targeting cytotoxic T lymphocyte associated antigen 4 (CTLA-4) are also undergoing clinical trials. Researches on immune checkpoint inhibitors have been rapidly implemented in a variety of different types of lung cancer, such as small cell lung cancer (SCLC) and locally advanced NSCLC, and these inhibitors began to be applied in combination with some established treatments, including chemotherapy, targeting therapy and radiotherapy...
April 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28447257/recent-developments-in-radiotherapy-for-small-cell-lung-cancer-a-review-by-the-oncologic-group-for-the-study-of-lung-cancer-spanish-radiation-oncology-society
#4
REVIEW
N Rodriguez de Dios, P Calvo, M Rico, M Martín, F Couñago, A Sotoca, B Taboada, A Rodríguez
Small-cell lung cancer (SCLC) accounts for 13% of all lung tumours. The standard treatment in patients with limited-stage disease is radiotherapy combined with chemotherapy. In extensive SCLC, the importance of consolidation thoracic radiotherapy in patients with a good treatment response has become increasingly recognized. In both limited and extensive disease, prophylactic cranial irradiation is recommended in patients who respond to treatment. New therapeutic approaches such as immunotherapy are being increasingly incorporated into the treatment of SCLC, although more slowly than in non-small cell lung cancer (NSCLC)...
April 26, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28432275/better-cancer-specific-survival-in-young-small-cell-lung-cancer-patients-especially-with-ajcc-stage-iii
#5
Haiyong Wang, Jingze Zhang, Fang Shi, Chenyue Zhang, Qinghua Jiao, Hui Zhu
It has been reported that younger patients with non-small cell lung cancer (NSCLC) tend to have a better prognosis. Yet, few studies have focused on the clinicopathological characteristics and prognosis of young small cell lung cancer (SCLC), especially for patients with age < 50. In our study, we used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 16503 patients with SCLC including 711 patients aged < 50, 3338 patients aged 50-59, 5937 patients aged 60-69, 4649 patients aged 70-79 and 1868 patients aged ≥ 80 between 2010 and 2013...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28414324/correlation-between-histone-acetylation-and-expression-of-notch1-in-human-lung-carcinoma-and-its-possible-role-in-combined-small-cell-lung-carcinoma
#6
Wael Abdo Hassan, Shin-Ichiro Takebayashi, Mohamed Osama Ali Abdalla, Kosuke Fujino, Shinji Kudoh, Yamoto Motooka, Yonosuke Sato, Yoshiki Naito, Koichi Higaki, Joeji Wakimoto, Seiji Okada, Mituyoshi Nakao, Yuichi Ishikawa, Takaaki Ito
Combined small-cell lung carcinoma (cSCLC) is composed of small-cell lung carcinoma (SCLC) admixed with non-small-cell lung carcinoma (NSCLC). Evaluating the molecular differences between SCLC and NSCLC could lead to a better understanding of the pathogenesis of such neoplasms. Therefore, in this study, we investigated the correlation between histone acetylation and Notch1 expression in lung carcinoma. Using chromatin immunoprecipitation (ChIP) assay, we measured the level of acetylated histone H3 around the promoter region of Notch1 in SCLC and NSCLC cells...
April 17, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28410216/friend-leukemia-virus-integration-1-promotes-tumorigenesis-of-small-cell-lung-cancer-cells-by-activating-the-mir-17-92-pathway
#7
LingyuLi, Wei Song, Xu Yan, Ailing Li, Xiaoying Zhang, Wei Li, Xue Wen Lei Zhou, Dehai Yu, Ji-Fan Hu, Jiuwei Cui
Small cell lung cancer (SCLC) is regarded as the most devastative type of human lung malignancies. The rapid and disseminated growth pattern remains the primary cause of poor clinical prognosis in patients with SCLC. However, the molecular factors that drive rapid progression of SCLC remain unclear. Friend leukemia virus integration 1 (FLI1), an Ets transcription factor family member, has been previously reported to act as a major driver of hematological malignancies. In this study, we explored the potential role of FLI1 in SCLC...
March 30, 2017: Oncotarget
https://www.readbyqxmd.com/read/28405726/inter-heterogeneity-and-intra-heterogeneity-of-%C3%AE-v%C3%AE-3-in-non-small-cell-lung-cancer-and-small-cell-lung-cancer-patients-as-revealed-by-68-ga-rgd2-pet-imaging
#8
Fei Kang, Zhe Wang, Guoquan Li, Shengjun Wang, Daliang Liu, Mingru Zhang, Mingxuan Zhao, Weidong Yang, Jing Wang
PURPOSE: Integrin αvβ3 is the therapeutic target of the anti-angiogenic drug cilengitide. The objective of this study was to compare αvβ3 levels in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) patients, by using the positron emission tomography (PET) tracer (68)Ga-labeled dimerized-RGD ((68)Ga-RGD2). METHODS: Thirty-one patients with pathologically confirmed lung cancer were enrolled (21 were NSCLC and 10 were SCLC). PET/CT images were acquired using (68)Ga-RGD2...
April 12, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28393715/hospitalization-costs-of-lung-cancer-diagnosis-in-turkey-is-there-a-difference-between-histological-types-and-stages
#9
Murat Türk, Fatma Yıldırım, Ahmet Selim Yurdakul, Can Öztürk
Introduction: To establish the direct costs of diagnosing lung cancer in hospitalized patients. Materials and Methods: Hospital data of patients who were hospitalized and diagnosed as lung cancer between September 2013 and August 2014 were retrospectively analyzed. Patients who underwent surgery for diagnosis and who were initiated with cancer treatment during the same hospital stay were excluded from study. Histological types and stages of lung cancer were determined...
December 2016: Tüberküloz Ve Toraks
https://www.readbyqxmd.com/read/28393006/small-cell-lung-cancer-transformation-during-immunotherapy-with-nivolumab-a-case-report
#10
Takuma Imakita, Kohei Fujita, Osamu Kanai, Tsuyoshi Terashima, Tadashi Mio
We report a rare case of transformation of non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC), without epidermal growth factor receptor (EGFR) gene mutation, during immunotherapy treatment with nivolumab. A 75-year-old man was referred to our hospital following the observation of a 64 mm mass in a chest computed tomography (CT) scan. A transbronchial biopsy of the mass identified the pathological presence of poorly differentiated NSCLC, with no histological signs of SCLC. No mutations were identified in the EGFR gene...
2017: Respiratory Medicine Case Reports
https://www.readbyqxmd.com/read/28386299/highlights-from-the-ecancer-future-horizons-in-lung-cancer-conference-1-2-september-2016-focusing-on-the-future-of-treatment-for-nsclc-and-sclc
#11
Kayleigh Bassiri, Linda Cairns, Gordon McVie, Michael Seckl
The 'Future Horizons in Lung Cancer' meeting was designed to bring leading scientists together alongside clinicians to discuss the most recent advances in lung cancer pathophysiology and treatment. The aim was to take those attending the event on a journey through decades of lung cancer research and understanding, with topics spanning from screening and surgical care to "omics" approaches for drug target and biomarker discovery. There were also several talks describing the role of radiotherapy in lung cancer and advancements in imaging techniques, aiding surgeons in their attempts to resect early lesions...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28366138/-hospitalization-costs-of-lung-cancer-diagnosis-in-turkey-is-there-a-difference-between-histological-types-and-stages
#12
Murat Türk, Fatma Yıldırım, Ahmet Selim Yurdakul, Can Öztürk
Introduction: To establish the direct costs of diagnosing lung cancer in hospitalized patients. Materials and Methods: Hospital data of patients who were hospitalized and diagnosed as lung cancer between September 2013 and August 2014 were retrospectively analyzed. Patients who underwent surgery for diagnosis and who were initiated with cancer treatment during the same hospital stay were excluded from study. Histological types and stages of lung cancer were determined...
December 2016: Tüberküloz Ve Toraks
https://www.readbyqxmd.com/read/28337370/role-of-epidermal-growth-factor-receptor-in-lung-cancer-and-targeted-therapies
#13
REVIEW
Tie-Cheng Liu, Xin Jin, Yan Wang, Ke Wang
Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers (SCLC), have responded effectively to chemo-, radiation and adjuvant-therapies. Tumor removal through surgery also appeared as a good therapeutic strategy. However, these therapies demonstrated unfavourable side-effects, and hence novel drugs targeting lung cancer emerged essential. Activation of epidermal growth factor receptor (EGFR)-tyrosine kinases is a key reason for lung cancer progression...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28325266/stage-i-small-cell-lung-cancer-a-new-potential-option-for-stereotactic-ablative-radiation-therapy-a-review-of-literature
#14
REVIEW
Filippo Alongi, Stefano Arcangeli, Berardino De Bari, Niccolò Giaj-Levra, Alba Fiorentino, Rosario Mazzola, Marco Trovò
Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC)...
April 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28285684/dual-occurrence-of-alk-g1202r-solvent-front-mutation-and-small-cell-lung-cancer-transformation-as-resistance-mechanisms-to-second-generation-alk-inhibitors-without-prior-exposure-to-crizotinib-pitfall-of-solely-relying-on-liquid-re-biopsy
#15
Sai-Hong Ignatius Ou, Thomas K Lee, Lauren Young, Maria Y Fernandez-Rocha, Dean Pavlick, Alexa B Schrock, Viola W Zhu, Jeffrey Milliken, Siraj M Ali, Barbara J Gitlitz
Development of the acquired ALK G1202R solvent front mutation and small cell lung cancer (SCLC) transformation have both been independently reported as resistance mechanisms to ALK inhibitors in ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) patients but have not been reported in the same patient. Here we report an ALK+ NSCLC patient who had disease progression after ceritinib and then alectinib where an ALK G1202R mutation was detected on circulating tumor (ct) DNA prior to enrollment onto a trial of another next generation ALK inhibitor, lorlatinib...
April 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28282545/nidogen-1-degraded-by-cathepsin-s-can-be-quantified-in-serum-and-is-associated-with-non-small-cell-lung-cancer
#16
Nicholas Willumsen, Cecilie L Bager, Diana J Leeming, Anne-Christine Bay-Jensen, Morten A Karsdal
Loss of basement membrane (BM) integrity is typically associated with cancer. Nidogen-1 is an essential component of the BM. Nidogen-1 is a substrate for cathepsin-S (CatS) which is released into the tumor microenvironment. Measuring nidogen-1 degraded by CatS may therefore have biomarker potential in cancer. The aim of this study was to investigate if CatS-degraded nidogen-1 was detectable in serum and a possible biomarker for cancer, a pathology associated with disruption of the BM. A competitive enzyme-linked immunosorbent assay (NIC) was developed with a monoclonal mouse antibody specific for a CatS cleavage site on human nidogen-1...
April 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28252315/checkpoint-blockade-in-lung-cancer-and-mesothelioma
#17
Lysanne A Lievense, Daniel H Sterman, Robin Cornelissen, Joachim G Aerts
In the past decade, immunotherapy has emerged as a new treatment modality in cancer. The most success has been achieved with the class of checkpoint inhibitors; antibodies which unleash the anti-tumor immune response. Following the success in melanoma, numerous clinical trials are being conducted investigating checkpoint inhibitors in lung cancer and mesothelioma. The programmed death protein 1-protein death ligand 1/2 (PD-1 - PD-L1/2) pathway and cytotoxic T-lymphocyte associated protein 4 (CTLA4) are currently the most studied immunotherapeutic targets in these malignancies...
March 2, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28230005/current-mechanism-of-acquired-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-and-updated-therapy-strategies-in-human-nonsmall-cell-lung-cancer
#18
REVIEW
Kaixian Zhang, Qianqian Yuan
Lung cancer continues to be a major health problem and the most common cancer-related mortality worldwide with about 80%-85% patients suffering from nonsmall cell lung cancer (NSCLC). More than 80% of NSCLC cases are often diagnosed as advanced stage and harbor epidermal growth factor receptor (EGFR) activating mutation. Although great success in initial response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) are found in EGFR-mutant NSCLC patients, acquired resistance usually occurs on the continuous treatment...
December 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28203418/clinical-outcomes-of-surgically-resected-combined-small-cell-lung-cancer-a-two-institutional-experience
#19
Chao Zhang, Haitang Yang, Heng Zhao, Baoping Lang, Xiangdong Yu, Peng Xiao, Xiao Zhang
BACKGROUND: The combined small cell lung cancer (c-SCLC) was rare and its clinicopathological characteristics had not been thoroughly described. The aim of this study was to determine prognostic factors and survival in c-SCLC patients. METHODS: Clinical records of patients with c-SCLC who underwent surgery between January 2009 and December 2013 in two institutions were retrospectively reviewed. RESULTS: Ninety-seven patients were identified...
January 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28149764/third-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-t790m-positive-non-small-cell-lung-cancer-review-on-emerged-mechanisms-of-resistance
#20
REVIEW
Roberta Minari, Paola Bordi, Marcello Tiseo
Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approximately 10 months...
December 2016: Translational Lung Cancer Research
keyword
keyword
13192
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"